Skip to content
NewsBlazeAU – Lifestyle
Author:
Mighty Therapeutics
Mighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted Medicines
July 14, 2026
Mighty Therapeutics Announces First Patient Dosed in Phase 4 Confirmatory Study of Elamipretide in Barth Syndrome
July 8, 2026